We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
RedHill (RDHL) Stock Up on Positive Phase I Data on Yeliva
Read MoreHide Full Article
RedHill Biopharma Ltd.’s (RDHL - Free Report) shares gained 2.6% after the company announced positive results of a phase I study on Yeliva (ABC294640) for the treatment of advanced solid tumors.
The open-label, dose-escalation, pharmacokinetic (PK) and pharmacodynamic (PD) study evaluated Yeliva in patients (n=21) with advanced solid tumors, with the majority suffering from gastrointestinal cancer such as pancreatic, colorectal and cholangiocarcinoma cancers.
Data from the study demonstrated that Yeliva can be safely administered to cancer patients at doses providing circulating drug levels that are predicted to have therapeutic activity.
The primary objectives included the determination of the maximum tolerated dose, dose limiting toxicities and evaluating the safety of Yeliva, while the secondary objective was to establish the PK and PD properties of the candidate. The study met both the primary and secondary endpoints, and the candidate was found to be safe and well tolerated.
Meanwhile, a number of studies on Yeliva are expected to begin in the coming months. RedHill Biopharma expects to initiate a phase I/II study on the candidate for the treatment of refractory or relapsed multiple myeloma in the coming weeks. In addition, the company plans to evaluate Yeliva in a phase II study as a radioprotectant for the prevention of mucositis in cancer patients undergoing therapeutic radiotherapy in the second half of 2016, and in a phase II study for the treatment of advanced hepatocellular carcinoma in the third quarter of 2016.
We note that the company is also progressing with other candidates in its pipeline. Earlier this week, the company initiated a phase II study on Bekinda (12 mg) for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D). The randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of Bekinda in patients with IBS-D.
Going ahead, we expect investors to focus on further pipeline updates on the company.
RedHill Biopharma currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Bristol-Myers Squibb Company (BMY - Free Report) , ANI Pharmaceuticals, Inc. (ANIP - Free Report) and Pfizer Inc. (PFE - Free Report) , each sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
RedHill (RDHL) Stock Up on Positive Phase I Data on Yeliva
RedHill Biopharma Ltd.’s (RDHL - Free Report) shares gained 2.6% after the company announced positive results of a phase I study on Yeliva (ABC294640) for the treatment of advanced solid tumors.
The open-label, dose-escalation, pharmacokinetic (PK) and pharmacodynamic (PD) study evaluated Yeliva in patients (n=21) with advanced solid tumors, with the majority suffering from gastrointestinal cancer such as pancreatic, colorectal and cholangiocarcinoma cancers.
Data from the study demonstrated that Yeliva can be safely administered to cancer patients at doses providing circulating drug levels that are predicted to have therapeutic activity.
The primary objectives included the determination of the maximum tolerated dose, dose limiting toxicities and evaluating the safety of Yeliva, while the secondary objective was to establish the PK and PD properties of the candidate. The study met both the primary and secondary endpoints, and the candidate was found to be safe and well tolerated.
Meanwhile, a number of studies on Yeliva are expected to begin in the coming months. RedHill Biopharma expects to initiate a phase I/II study on the candidate for the treatment of refractory or relapsed multiple myeloma in the coming weeks. In addition, the company plans to evaluate Yeliva in a phase II study as a radioprotectant for the prevention of mucositis in cancer patients undergoing therapeutic radiotherapy in the second half of 2016, and in a phase II study for the treatment of advanced hepatocellular carcinoma in the third quarter of 2016.
We note that the company is also progressing with other candidates in its pipeline. Earlier this week, the company initiated a phase II study on Bekinda (12 mg) for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D). The randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of Bekinda in patients with IBS-D.
Going ahead, we expect investors to focus on further pipeline updates on the company.
RedHill Biopharma currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Bristol-Myers Squibb Company (BMY - Free Report) , ANI Pharmaceuticals, Inc. (ANIP - Free Report) and Pfizer Inc. (PFE - Free Report) , each sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>